当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Gilberto Ruiz
The pharmaceutical industry is undergoing significant transformation driven by new technologies, changing patient expectations, and increasing competition. This transformation is leading to several key innovations and trends, including personalized medicine, gene editing, digital health technologies, artificial intelligence, new business models, regulatory innovation, and collaborative innovation.
Personalized medicine aims to provide more targeted and effective treatments by analysing individual patient's genetics, lifestyle, and environmental factors. Gene editing holds the promise of curing or preventing genetic diseases by precisely editing the patient's DNA. Digital health technologies enable patients to monitor their health remotely, receive personalized treatment recommendations, and communicate with their doctors from anywhere.
Artificial intelligence is being used to identify potential drug targets and design more efficient clinical trials, as well as develop predictive models for patient outcomes. New business models, such as value-based pricing and niche market focus, are being explored to adapt to increasing competition and pressure to reduce healthcare costs. Regulatory innovation, including expedited drug approval processes and the use of real-world evidence, is also changing the landscape.